Suppr超能文献

基于非房室或基于模型分析的个体估算的生物等效性检验:不同设计的样本均值估计值和 I 类错误的评估。

Bioequivalence tests based on individual estimates using non-compartmental or model-based analyses: evaluation of estimates of sample means and type I error for different designs.

机构信息

INSERM UMR 738, Université Paris Diderot, 16 rue Henri Huchard, 75018, Paris, France.

出版信息

Pharm Res. 2010 Jan;27(1):92-104. doi: 10.1007/s11095-009-9980-5. Epub 2009 Oct 30.

Abstract

PURPOSE

The main objective of this work is to compare the standard bioequivalence tests based on individual estimates of the area under the curve and the maximal concentration obtained by non-compartmental analysis (NCA) to those based on individual empirical Bayes estimates (EBE) obtained by nonlinear mixed effects models.

METHODS

We evaluate by simulation the precision of sample means estimates and the type I error of bioequivalence tests for both approaches. Crossover trials are simulated under H ( 0 ) using different numbers of subjects (N) and of samples per subject (n). We simulate concentration-time profiles with different variability settings for the between-subject and within-subject variabilities and for the variance of the residual error.

RESULTS

Bioequivalence tests based on NCA show satisfactory properties with low and high variabilities, except when the residual error is high, which leads to a very poor type I error, or when n is small, which leads to biased estimates. Tests based on EBE lead to an increase of the type I error, when the shrinkage is above 20%, which occurs notably when NCA fails.

CONCLUSIONS

For small n or data with high residual error, tests based on a global data analysis should be considered instead of those based on individual estimates.

摘要

目的

本研究的主要目的是比较基于个体曲线下面积和非房室分析(NCA)获得的最大浓度的个体估计的标准生物等效性检验与基于非线性混合效应模型获得的个体经验贝叶斯估计(EBE)的检验。

方法

我们通过模拟评估了这两种方法的样本均值估计的精度和生物等效性检验的Ⅰ类错误。在 H(0)下,我们使用不同数量的受试者(N)和每个受试者的样本数(n)来模拟交叉试验。我们模拟了具有不同的个体间和个体内变异性以及残差误差方差设置的浓度-时间曲线。

结果

基于 NCA 的生物等效性检验具有良好的性质,无论是在低变异性还是高变异性的情况下,除了当残差误差较高时,这会导致非常差的Ⅰ类错误,或者当 n 较小时,这会导致有偏差的估计。当收缩率超过 20%时,基于 EBE 的检验会导致Ⅰ类错误增加,这在 NCA 失败时尤为明显。

结论

对于 n 较小或残差误差较高的数据,应该考虑基于全局数据分析的检验,而不是基于个体估计的检验。

相似文献

5
Controlling type 1 error rate for sequential, bioequivalence studies with crossover designs.
Pharm Stat. 2019 Jan;18(1):96-105. doi: 10.1002/pst.1911. Epub 2018 Oct 29.
6
Efficient model-based bioequivalence testing.
Biostatistics. 2022 Jan 13;23(1):314-327. doi: 10.1093/biostatistics/kxaa026.
7
On statistical power for average bioequivalence testing under replicated crossover designs.
J Biopharm Stat. 2002 Aug;12(3):295-309. doi: 10.1081/bip-120014560.

引用本文的文献

2
Evaluation of model-integrated evidence approaches for pharmacokinetic bioequivalence studies using model averaging methods.
CPT Pharmacometrics Syst Pharmacol. 2024 Oct;13(10):1748-1761. doi: 10.1002/psp4.13217. Epub 2024 Aug 28.
3
Development and comparison of model-integrated evidence approaches for bioequivalence studies with pharmacokinetic end points.
CPT Pharmacometrics Syst Pharmacol. 2024 Oct;13(10):1734-1747. doi: 10.1002/psp4.13216. Epub 2024 Aug 23.
4
A Bayesian framework for virtual comparative trials and bioequivalence assessments.
Front Pharmacol. 2024 Jul 30;15:1404619. doi: 10.3389/fphar.2024.1404619. eCollection 2024.
5
Evaluation of model-based bioequivalence approach for single sample pharmacokinetic studies.
CPT Pharmacometrics Syst Pharmacol. 2023 Jul;12(7):904-915. doi: 10.1002/psp4.12960. Epub 2023 Apr 27.
6
Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling.
Clin Pharmacokinet. 2022 Nov;61(11):1585-1593. doi: 10.1007/s40262-022-01163-w. Epub 2022 Sep 30.
7
Impact of model misspecification on model-based tests in PK studies with parallel design: real case and simulation studies.
J Pharmacokinet Pharmacodyn. 2022 Oct;49(5):557-577. doi: 10.1007/s10928-022-09821-z. Epub 2022 Sep 16.

本文引用的文献

1
Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.
AAPS J. 2009 Sep;11(3):558-69. doi: 10.1208/s12248-009-9133-0. Epub 2009 Aug 1.
2
Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.
J Pharmacokinet Pharmacodyn. 2009 Aug;36(4):317-39. doi: 10.1007/s10928-009-9124-x. Epub 2009 Jun 27.
3
Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART.
Eur J Clin Pharmacol. 2009 Jul;65(7):667-78. doi: 10.1007/s00228-009-0660-5. Epub 2009 May 14.
4
Extension of the SAEM algorithm for nonlinear mixed models with 2 levels of random effects.
Biostatistics. 2009 Jan;10(1):121-35. doi: 10.1093/biostatistics/kxn020. Epub 2008 Jun 25.
8
Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters.
Eur J Clin Pharmacol. 2007 May;63(5):437-49. doi: 10.1007/s00228-007-0269-5. Epub 2007 Mar 13.
9
Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software.
J Pharmacokinet Pharmacodyn. 2007 Apr;34(2):229-49. doi: 10.1007/s10928-006-9043-z. Epub 2007 Jan 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验